LBL-007
- Generic Name
- LBL-007
A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma
- Conditions
- Esophageal CancerEsophageal Squamous Cell CarcinomaEsophageal Squamous Cell Carcinoma by AJCC V8 Stage
- Interventions
- First Posted Date
- 2023-08-24
- Last Posted Date
- 2025-01-15
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 118
- Registration Number
- NCT06010303
- Locations
- 🇨🇳
Changhua Christian Hospital, Changhua, Taiwan
🇨🇳Kaohsiung Medical University Chung Ho Memorial Hospital, Kaohsiung, Taiwan
🇨🇳China Medical University Hospital, Taichung, Taiwan
Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma
- Conditions
- Head and Neck Squamous Cell CarcinomaHead and Neck Cancer
- Interventions
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 160
- Registration Number
- NCT05909904
- Locations
- 🇹ðŸ‡
Siriraj Hospital, Bangkok, Thailand
🇹ðŸ‡Ramathibodi Hospital Mahidol University, Bangkok, Thailand
🇰🇷Keimyung University Dongsan Hospital, Dalseogu, Daegu Gwang'yeogsi, Korea, Republic of
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer
- Conditions
- Non-small Cell Lung CancerMetastatic Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2022-12-02
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 400
- Registration Number
- NCT05635708
- Locations
- 🇮🇹
Regina Elena, Istituto Nazionale Dei Tumori, Ifo, Irccs, Roma, Italy
🇮🇹Centro Ricerche Cliniche Di Verona, Verona, Italy
🇲🇾Tengku Ampuan Afzan Hospital, Kuantan, Malaysia
A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer
- Conditions
- Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer
- Interventions
- First Posted Date
- 2022-11-08
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 113
- Registration Number
- NCT05609370
- Locations
- 🇺🇸
Baptist Md Anderson Cancer Center, Jacksonville, Florida, United States
🇺🇸Alaska Oncology and Hematology, Llc, Anchorage, Alaska, United States
🇺🇸Banner Md Anderson Cancer Center, Gilbert, Arizona, United States
Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2022-10-13
- Last Posted Date
- 2025-03-03
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 121
- Registration Number
- NCT05577702
- Locations
- 🇨🇳
Hwa Mei Hospital, University of Chinese Academy of Sciences (Ningbo No Hospital), Ningbo, Zhejiang, China
🇨🇳The First Affiliated Hospital of Wannan Medical College, Wuhu, Anhui, China
🇨🇳Beijing Cancer Hospital, Beijing, Beijing, China
A Study to Assess LBL-007 in Combination With Toripalimab and Axitinib Tablets Subjects With Advanced Melanoma
- Conditions
- Advanced Melanoma
- Interventions
- First Posted Date
- 2020-11-23
- Last Posted Date
- 2025-01-15
- Lead Sponsor
- Nanjing Leads Biolabs Co.,Ltd
- Target Recruit Count
- 88
- Registration Number
- NCT04640545
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, China
🇨🇳Hunan Cancer Hospital, Changsha, Hunan, China
Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies
- First Posted Date
- 2019-11-15
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 430
- Registration Number
- NCT04164199
- Locations
- 🇨🇳
Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
🇺🇸Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States
🇺🇸Memorial Sloan Kettering Cancer Center Mskcc, New York, New York, United States
Study of BGB-A425 and LBL-007 in Combination With Tislelizumab in Advanced Solid Tumors
- Conditions
- Locally Advanced or Metastatic Solid Tumors for Phase 1,Dose Escalation and Phase 2 Safety Lead-in, HNSCC, NSCLC and RCC Participants for Phase 2
- Interventions
- First Posted Date
- 2018-11-16
- Last Posted Date
- 2025-02-14
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 114
- Registration Number
- NCT03744468
- Locations
- 🇺🇸
Chao Family Comprehensive Cancer Center, Orange, California, United States
🇺🇸University of Colorado Cancer Center, Aurora, Colorado, United States
🇺🇸University of Chicago Medical Center, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.